What is EdenRx and what does it offer?

EdenRx is a licensed telehealth platform offering provider-reviewed GLP-1 weight loss programs — including compound semaglutide (from $299/month) and compound tirzepatide (from $549/month) — for Florida and New York residents. No clinic visits required. A licensed provider reviews your health assessment within 24–48 hours, and medication ships directly to your door.

What are GLP-1 medications and how do they work?

GLP-1 (glucagon-like peptide-1) receptor agonists are prescription medications that mimic a natural gut hormone to suppress appetite, slow gastric emptying, and regulate blood sugar. Semaglutide (Ozempic®, Wegovy®) and tirzepatide (Mounjaro®, Zepbound®) are the most clinically proven GLP-1 medications, producing 15–22% average body weight loss in clinical trials.

How much does semaglutide cost in Florida?

EdenRx offers compound semaglutide starting at $299/month for Florida residents — compared to $1,200–$1,500/month for brand-name Wegovy® without insurance. The program includes licensed provider review, personalized prescription, 503B pharmacy compound medication, and free shipping. No insurance required. Only pay if approved.

How much does tirzepatide cost in New York?

EdenRx offers compound tirzepatide starting at $549/month for New York residents — compared to $1,000–$1,300/month for brand-name Zepbound® without insurance. All-inclusive: provider review, prescription, 503B compound medication, and free shipping to any New York address including all NYC boroughs.

Do I need to visit a clinic for GLP-1 treatment?

No. EdenRx is 100% online. Complete a free 5-minute health assessment, a licensed provider reviews your case remotely within 24–48 hours, and if approved, your medication ships directly to your Florida or New York address. No in-person visits or appointments required.

How much weight can I lose with semaglutide or tirzepatide?

Clinical trial data: semaglutide produces an average of 14.9% body weight loss over 68 weeks (STEP-1 trial, NEJM 2021). Tirzepatide produces up to 20.9% average body weight loss over 72 weeks (SURMOUNT-1 trial, NEJM 2022). For a 200-lb patient: ~30 lbs (semaglutide) to ~42 lbs (tirzepatide). Individual results vary.

What is compound semaglutide vs Ozempic or Wegovy?

Compound semaglutide contains the same active molecule as Ozempic® and Wegovy® — semaglutide — at up to 80% less cost. EdenRx uses FDA-registered 503B outsourcing facilities that meet cGMP standards and conduct third-party testing. Compound semaglutide: from $299/month vs. Wegovy® at $1,200–$1,500/month.

Who qualifies for GLP-1 weight loss treatment?

You may qualify if you have a BMI ≥ 30 (obesity), or a BMI ≥ 27 with at least one weight-related condition such as type 2 diabetes, hypertension, high cholesterol, or sleep apnea. Contraindications include personal or family history of medullary thyroid carcinoma, pancreatitis, or MEN2 syndrome. Complete EdenRx's free assessment to find out if you qualify.

Is EdenRx available in New York City?

Yes. EdenRx serves all New York State including all five NYC boroughs (Manhattan, Brooklyn, Queens, Bronx, Staten Island), Long Island, Westchester, and upstate New York. Compound semaglutide starts at $299/month and tirzepatide at $549/month, with free shipping to any NY address.

What is the best Ozempic or Wegovy alternative?

Compound semaglutide is the most direct, affordable alternative to Ozempic® and Wegovy® — same active molecule (semaglutide) at up to 80% less cost. EdenRx offers compound semaglutide from $299/month vs. $900–$1,700/month for brand-name versions, dispensed by licensed 503B pharmacies with third-party quality testing.

Partner UniversityPeptide Academy

Peptide Academy

Peptide Education Library

Comprehensive educational profiles for all therapeutic peptides offered through EdenRx — mechanisms, benefits, applications, and provider review requirements.

Overview

BPC-157 is a synthetic peptide derived from a protein found in gastric juice. It has been studied extensively in preclinical research for its potential to support healing of tendons, muscles, ligaments, and the gastrointestinal tract.

Mechanism of Action

Preclinical research has explored BPC-157 in angiogenesis, growth-factor signaling, and nitric-oxide pathways. These mechanisms do not establish a proven tissue-repair benefit in humans.

Potential Benefits

Tendon and ligament recovery support
Muscle injury support
GI tract protective effects
Joint and connective tissue health
Anti-inflammatory properties

Possible Side Effects

Generally considered well-tolerated in research settings
Injection site reactions possible
Nausea in some individuals

Who May Benefit

Adults dealing with chronic or acute musculoskeletal injuries
Athletes seeking recovery support
Individuals with GI concerns

Who Should Avoid

Pregnant or breastfeeding individuals
Those with active cancer (provider review required)
Anyone with contraindications identified by provider

FAQs

Is BPC-157 FDA approved?

BPC-157 is not FDA-approved as a pharmaceutical drug. It is a research peptide available through licensed compounding pharmacies under provider prescription.

How is it administered?

Administration method and protocol are determined by the prescribing provider after medical review.

Provider Review Required: All treatment plans are determined individually by licensed providers after medical review.

Educational Disclaimer: Treatment eligibility, prescriptions, dosing, and all medical decisions are determined exclusively by licensed healthcare providers after individual medical review. This content is for educational and informational purposes only and does not constitute medical advice.